Plasma Derived Therapy Market Size & Growth Forecast 2027–2036, By Segments (Product, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Plasma Derived Therapy Market size was valued at USD 44.3 Billion in 2026 and is anticipated to grow at 7.95% CAGR from 2027 to 2036, crossing USD 95.2 Billion by 2036. The industry revenue for 2027 is estimated at USD 47.29 Billion.
Get more details on this report
Request Free Sample ReportPlasma Derived Therapy Market Intelligence Snapshot
Regional Market Dynamics
- North America held 53.77% of the market in 2026, supported by advanced healthcare infrastructure, established plasma collection and processing, and strong treatment demand.
- Asia Pacific is growing fastest as healthcare infrastructure, plasma collection capabilities, healthcare spending, and access to specialized medical care continue improving.
Segment Momentum
- Immunoglobulins held a 50.99% share in 2026 and remain the fastest-growing product segment due to their extensive use in treating immune deficiencies, autoimmune disorders, and neurological conditions, supported by expanding therapeutic applications and improved treatment accessibility.
- Primary immunodeficiency diseases are the fastest-growing application because improved disease awareness, wider diagnostic capabilities, greater healthcare access, and increasing use of immunoglobulin replacement therapies are accelerating treatment adoption.
Market Expansion Drivers
- Rising prevalence of rare and genetic disorders driving demand for plasma-derived therapeutics
- Expansion of plasma collection centers improving global supply chain capacity for biologics
- Increasing adoption of immunoglobulin therapies expanding treatment scope across autoimmune conditions
Leading Market Participants
- Top companies in the plasma derived therapy market include CSL Behring (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), Biotest AG (Germany), ADMA Biologics, Inc. (United States), Kamada Ltd. (Israel), SK Plasma Co., Ltd. (South Korea)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 44.3 Billion
- 2027 Estimated Market Size: USD 47.29 Billion
- Projected Market Size: USD 95.2 Billion by 2036
- Growth Forecast: 7.95% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Immunoglobulins (Product) | Haemophilia (Application)
- Emerging Opportunity Segment: Immunoglobulins (Product) | Primary Immunodeficiency Diseases (Application)
Market Growth Drivers and Industry Trends
Rising prevalence of rare and genetic disorders driving demand for plasma-derived therapeutics
The increasing incidence of rare and inherited disorders is strengthening the need for specialized biological treatments, which will drive the plasma derived therapy market growth. Plasma-derived therapeutics play an important role in managing conditions associated with immune deficiencies, coagulation disorders, and other complex diseases where long-term treatment is often required. As diagnostic capabilities improve and patient identification becomes more widespread, healthcare providers are expanding the use of these therapies within specialized clinical care pathways.
Expansion of plasma collection centers improving global supply chain capacity for biologics
Growing investment in plasma collection infrastructure is enhancing the availability of essential raw materials, making the plasma derived therapy market more resilient to increasing global treatment demand. Expanded collection networks improve plasma sourcing capacity, strengthen manufacturing continuity, and support a more reliable supply chain for plasma-derived biologics. Improved logistics, processing capabilities, and donor accessibility also contribute to greater production efficiency while helping meet rising healthcare requirements across multiple regions.
Increasing adoption of immunoglobulin therapies expanding treatment scope across autoimmune conditions
The expanding clinical use of immunoglobulin therapies is creating broader therapeutic opportunities, and the plasma derived therapy market is benefiting from their growing application in autoimmune disease management. Immunoglobulin products are increasingly incorporated into treatment protocols for patients requiring immune modulation, particularly in cases where conventional therapies provide limited clinical benefit. Continued advances in clinical practice and physician awareness are supporting wider utilization across diverse autoimmune and immune-mediated conditions without compromising individualized patient care.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of rare and genetic disorders driving demand for plasma-derived therapeutics | 2% | High | North America, Europe | High | Near Term |
| Expansion of plasma collection centers improving global supply chain capacity for biologics | 1.8% | High | North America, Asia Pacific | High | Mid Term |
| Increasing adoption of immunoglobulin therapies expanding treatment scope across autoimmune conditions | 1.7% | High | Europe, Asia Pacific | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the plasma derived therapy market at 53.77% in 2026, supported by advanced healthcare infrastructure, established plasma collection and processing capabilities, and strong demand for plasma-derived treatments. The region benefits from broad access to specialized healthcare services and well-developed systems for the diagnosis and management of conditions requiring plasma-based therapies. Continued investment in healthcare technologies and increasing emphasis on effective treatment options are further reinforcing regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to register the fastest growth in the plasma derived therapy market, driven by improving healthcare infrastructure, rising awareness of plasma-derived treatments, and expanding access to specialized medical care. Growing healthcare expenditure and the development of plasma collection and processing capabilities are creating a stronger foundation for regional supply. Increasing diagnosis of conditions requiring therapeutic interventions, alongside efforts to improve treatment accessibility, is also supporting market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Plasma Collection NetworkThe U.S. plasma derived therapy market is supported by extensive plasma collection infrastructure and strong demand for immunology and rare disease treatments. U.S. healthcare providers continue expanding access to plasma-based therapies while manufacturers invest in processing efficiency and product availability.
Germany 🇩🇪
Biopharmaceutical Processing ExpertiseGermany strengthens the plasma derived therapy market through advanced biopharmaceutical manufacturing capabilities and rigorous quality standards. German companies focus on optimizing plasma fractionation processes and supplying therapies for immune deficiencies, neurological disorders, and critical care applications.
Japan 🇯🇵
Specialized Therapeutic DemandJapan prioritizes plasma derived therapies for chronic disease management and specialized clinical applications supported by established healthcare systems. Japanese manufacturers emphasize product quality, patient safety, and efficient distribution of plasma-based treatments across hospitals and specialty clinics.
South Korea 🇰🇷
Healthcare Capacity EnhancementSouth Korea continues expanding the plasma derived therapy market by strengthening domestic biopharmaceutical capabilities and improving treatment accessibility. South Korean healthcare providers support broader adoption of plasma-derived products for immune disorders while encouraging local manufacturing development.
France 🇫🇷
Clinical Treatment OptimizationFrance supports the plasma derived therapy market through structured healthcare programs and continued use of plasma-based medicines in specialized treatment pathways. French stakeholders emphasize reliable supply management and clinical effectiveness for patients requiring long-term plasma-derived therapies.
Italy 🇮🇹
Hospital Care IntegrationItaly advances the plasma derived therapy market by integrating plasma-based medicines into hospital treatment protocols for immunology and hematology. Italian healthcare institutions prioritize consistent product availability and efficient patient management through coordinated procurement and clinical practice.
Segment Leadership and Growth Trends
Plasma Derived Therapy Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Immunoglobulins (Largest & Fastest-Growing Segment)
The immunoglobulins segment led the plasma derived therapy market with a 50.99% share in 2026 while also representing the fastest-growing product category. Its strong position is driven by the broad clinical use of immunoglobulin therapies in treating immune deficiencies, autoimmune disorders, and a wide range of neurological conditions. Increasing diagnosis of immune-related diseases, expanding therapeutic indications, and growing awareness of plasma-derived treatments continue to support sustained demand. Ongoing improvements in plasma collection, fractionation technologies, and treatment accessibility are further reinforcing the segment's leadership across global healthcare systems.
Application Segment Analysis: Haemophilia (Largest Segment) vs Primary Immunodeficiency Diseases (Fastest-Growing Segment)
The haemophilia segment held the largest share in 2026. Its dominance is supported by the long-term requirement for plasma-derived coagulation factor therapies to manage bleeding episodes and prevent disease-related complications. Continued improvements in disease diagnosis, greater access to replacement therapies, and increasing emphasis on comprehensive patient management have strengthened the segment's leading position.
The primary immunodeficiency diseases segment is anticipated to record the fastest growth in the plasma derived therapy market as awareness of inherited immune disorders continues to improve and diagnostic capabilities become more widely available. Rising utilization of immunoglobulin replacement therapies, together with expanding healthcare access and earlier disease identification, is expected to accelerate treatment adoption and support rapid segment growth.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Immunoglobulins, Coagulation Factors, Albumin, Others | Immunoglobulins | Immunoglobulins |
| Application | Haemophilia, Primary Immunodeficiency Diseases, Idiopathic/Immune Thrombocytopenic Purpura (ITP), Others | Haemophilia | Primary Immunodeficiency Diseases |
Competitive Landscape and Market Positioning
Major players in the plasma derived therapy market:
- CSL Behring (Australia)
- Takeda Pharmaceutical Company Limited (Japan)
- Grifols S.A. (Spain)
- Octapharma AG (Switzerland)
- Kedrion S.p.A. (Italy)
- Biotest AG (Germany)
- ADMA Biologics, Inc. (United States)
- Kamada Ltd. (Israel)
- SK Plasma Co., Ltd. (South Korea)
The competitive environment in the plasma derived therapy market is being reshaped by the growing importance of supply security, technological capabilities, and specialized therapeutic expertise. Companies are increasingly differentiating themselves through investments in plasma collection networks, processing efficiency, and quality control systems as access to reliable raw material becomes a key competitive advantage. Established participants are strengthening their positions by expanding operational capabilities across the value chain, while emerging players are exploring opportunities through innovation in plasma fractionation and treatment development. The market continues to experience strategic pressure as organizations seek to balance manufacturing complexity, regulatory requirements, and the need for broader patient access, creating a landscape where operational scale and scientific advancement increasingly influence competitive positioning.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| CSL Behring (Australia) | |||||||
| Takeda Pharmaceutical Company Limited (Japan) | |||||||
| Grifols S.A. (Spain) | |||||||
| Octapharma AG (Switzerland) | |||||||
| Kedrion S.p.A. (Italy) | |||||||
| Biotest AG (Germany) | |||||||
| ADMA Biologics Inc. (United States) | |||||||
| Kamada Ltd. (Israel) | |||||||
| SK Plasma Co. Ltd. (South Korea) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| GC Biopharma | May-26 | GC Biopharma executed a strategic memorandum of understanding with Merck Life Science to co-develop biopharmaceutical manufacturing processes. The collaboration optimizes good manufacturing practice (GMP) efficiencies, improving yield and supply chain stability for high-demand plasma-derived fractions and immunoglobulin therapies. |
| Takeda | Jul-25 | Takeda obtained FDA clearance for its HyHub and HyHub Duo administration devices designed specifically for HyQvia. The product innovation streamlines the setup for subcutaneous immunoglobulin infusion therapy, reducing preparation steps for multi-vial dosages to improve patient-led care. |
| Grifols | Jul-20 | Grifols signed a definitive agreement with GC Pharma to acquire its Montreal-based plasma fractionation facility, alongside 11 U.S. plasma collection centers and two specialized purification sites. The acquisition scales Grifols' North American manufacturing footprint and expands its primary raw material sourcing infrastructure. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Plasma Derived Therapy Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Treatment Setting | Hospitals, Specialty Clinics, Ambulatory Care Centers, Homecare |
| Plasma Source | Recovered Plasma, Source Plasma, Convalescent Plasma |
| Route of Administration | Intravenous, Subcutaneous, Intramuscular |
Plasma Derived Therapy Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Plasma Supply Resilience |
|
| Fractionation Economics |
|
| Patient Access & Treatment Continuity |
|
Need a different cut of the data?
Request Custom ResearchHow large is the plasma derived therapy market?
How is the plasma derived therapy industry expected to grow over the next 10 years?
How are rare and genetic disorders driving demand in the plasma derived therapy market?
Why is plasma collection infrastructure becoming strategically important for the plasma derived therapy market?
Why do immunoglobulins lead the plasma derived therapy market?
What is driving the rapid growth of plasma-derived therapies for primary immunodeficiency diseases?
Why does North America lead the plasma derived therapy market?
What is driving plasma derived therapy growth in Asia Pacific?
Who holds a significant market share in the plasma derived therapy landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization